The treatment of tuberculosis currently requires a minimum of six months of chemotherapy. Reducing this duration to four months would improve patient compliance and would consequently reduce transmission of tuberculosis in the community. This could be made possible if another drug, most probably a fluoroquinolone, was added to the current regimen. This proposal is about setting up a project for a clinical trial to test this hypothesis, with scientific teams from Europe and Africa working closely together.
The project consists of the writing of a protocol for a clinical trial for treatment of tuberculosis. This write up will associate European and African teams. The clinical trial will include three legs: 2 to test the 4 month regimes, the third being a therapeutic protocol on known efficiency. It will be necessary to:
Tuberculosis has been identified by the European Commission as a priority sickness linked to poverty. Reduction of the chemotherapy period is essential and necessary to improve the adherence of the patient to the treatment and therefore lower the propogation of the illness in the community. The development of a platform to undertake clinical trials is one of the objectives flagshipped in the domain “Confirming the international role of community research”
Union Internationale Contre la Tuberculose et les Maladies respiratoires
Bd. Saint Michel 68
75006 Paris, France
Tel: +33 1 44 32 03 71
Fax: +33 1 43 29 90 87